Video Journal of Biomedicine
December 17, 2025
A. Muzyk, F. Syed, Junjun Cong et al.
Abstract This study is the first to analyse real-world use of Auvelity (dextromethorphan HBr and bupropion HCL, 45 mg/105 mg extended-release tablets) for treating major depressive disorder (MDD) in the United States. Researchers reviewed medical records of over 22,000 adults, examining factors like age, gender, insurance, and previous depression treatments. Findings revealed that patients...
CNS Spectrums
April 1, 2023
Amanda Jones, Caroline Streicher, Shawn Alter et al.
AbstractBackgroundIn STAR*D, following non-remission with an SSRI, remission rates for second-line treatments were ~ 25%, regardless of the switch strategy employed. Antidepressants with novel mechanisms may improve outcomes in MDD. AXS-05 (dextromethorphan HBr 45 mg- bupropion HCl 105 mg) is a novel, oral, investigational, NMDA receptor antagonist with multimodal activity. The dextromethorphan...
CNS Spectrums
April 1, 2023
Amanda Jones, Caroline Streicher, Shawn Alter et al.
AbstractBackgroundAXS-05 (dextromethorphan-bupropion) is a novel, oral, investigational, NMDA receptor antagonist with multimodal activity being developed for MDD. The dextromethorphan component of AXS-05 is an NMDA receptor antagonist and a sigma-1 receptor agonist. The bupropion component of AXS-05 serves primarily to increase the bioavailability of dextromethorphan.MethodsAXS-05 was...
CNS Spectrums
April 1, 2023
Amanda Jones, Caroline Streicher, Shawn Alter et al.
AbstractBackgroundInnovative therapies to treat individuals with MDD, especially those with comorbid anxiety, are urgently needed.AXS-05 (dextromethorphan HBr 45 mg-bupropion HCl 105 mg) is a novel, oral, investigational NMDA receptor antagonist with multimodal activity. The dextromethorphan component of AXS-05 is an NMDA receptor antagonist and a sigma-1 receptor agonist. The bupropion...
CNS Spectrums
April 1, 2023
Amanda Jones, Roger S McIntyre, Mark Jacobsen et al.
AbstractBackgroundTreatments for MDD that can improve both overall depressive and anhedonic symptoms are urgently needed.AXS-05 (dextromethorphan-bupropion) is a novel, oral, investigational NMDA receptor antagonist with multimodal activity being developed for MDD. The dextromethorphan component of AXS-05 is an NMDA receptor antagonist and a sigma-1 receptor agonist. The bupropion component of...
Journal of Clinical Psychiatry
May 30, 2022
Dan V. Iosifescu, A. Jones, C. O'gorman et al.
Objective: Altered glutamatergic neurotransmission has been implicated in the pathogenesis of depression. This trial evaluated the efficacy and safety of AXS-05 (dextromethorphan-bupropion), an oral N-methyl-D-aspartate (NMDA) receptor antagonist and σ1 receptor agonist, in the treatment of major depressive disorder (MDD). Methods: This double-blind, phase 3 trial, was conducted between June...
American Journal of Psychiatry
May 18, 2022
Herriot Tabuteau, A. Jones, Ashley Anderson et al.
OBJECTIVE Altered glutamatergic neurotransmission is implicated in the pathogenesis of major depressive disorder. AXS-05 (dextromethorphan-bupropion) is an oral NMDA receptor antagonist and sigma-1 receptor agonist, which utilizes inhibition of CYP2D6 to increase its bioavailability. This phase 2 trial assessed the efficacy and safety of dextromethorphan-bupropion in the treatment of major...